The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer

Thelen P, Taubert H, Duensing S, Kristiansen G, Merseburger AS, Cronauer MV (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Aktuelle Urologie Georg Thieme Verlag

DOI: 10.1055/s-0043-115426

Abstract

A recently discovered mechanism enabling prostate cancer cells to escape the effects of endocrine therapies consists in the synthesis of C-terminally truncated, constitutively active androgen receptor (AR) splice variants (AR-V). Devoid of a functional C-terminal hormone/ligand binding domain, various AR-Vs are insensitive to therapies targeting the androgen/AR signalling axis. Preliminary studies suggest that AR-V7, the most common AR-V, is a promising predictive tumour marker and a relevant selection marker for the treatment of advanced prostate cancer. This review critically outlines recent advances in AR-V7 diagnostics and presents an overview of current AR-V7 targeted therapies.

Authors with CRIS profile

Helge Taubert Professur für Molekulare Urologie

Involved external institutions

Universitätsklinikum Göttingen DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Universitätsklinikum Bonn DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE)

How to cite

APA:

Thelen, P., Taubert, H., Duensing, S., Kristiansen, G., Merseburger, A.S., & Cronauer, M.V. (2018). The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer. Aktuelle Urologie. https://doi.org/10.1055/s-0043-115426

MLA:

Thelen, P., et al. "The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer." Aktuelle Urologie (2018).

BibTeX: Download